Sign in
Not yet taking people in United StatesNo phase

Looks at who completes or leaves melanoma clinical trials

Observes how often adults with melanoma finish or withdraw from clinical trials.

Key facts

Who runs it
Power Life Sciences Inc.
Where
San Francisco, United StatesSee the site
Trial code
Registry title
Investigating Participation Patterns Among Stage IV Melanoma Patients
Status
Not yet recruiting
People taking part
500 people, planned
Started
Nov 2024
Expected to end
Nov 2026
Type of study
Observational
Record updated
23 October 2023

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage IV melanoma who can understand the study and give informed consent.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Stage IV melanoma

Main reasons for not taking part

  • Women who are pregnant or nursing
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the trial
  • Cannot do regular electronic reporting

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Aged ≥ 18 years old
  • Diagnosis of stage IV melanoma
  • Able to comprehend the investigational nature of the protocol and provide informed consent

Who cannot take part

  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Female patients who are currently pregnant or nursing
  • Inability to perform regular electronic reporting

Where in United States

  • Power Life SciencesSan Francisco, United StatesContact: Michael B GillNot yet recruiting

About the trial

What the trial wants to find out

Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the safety and efficacy of new treatments for this disease. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation.

Read full original descriptionShow less

The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Understanding Patient Engagement Trends in Stage IV Melanoma Clinical Trials
Plain-language title
Looks at who completes or leaves melanoma clinical trialsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
23 October 2023